Known targets — ChEMBL curated mechanism
PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Zstk-474. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB known ✓ | P42338 | 19/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 14/20 | 1.00 |
| ▸ | PIK3CA known ✓ | P42336 | 13/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 12/20 | 1.00 |
| ▸ | PIK3R1 known ✓ | P27986 | 4/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zstk-474 SCHEMBL29357859 | 1.00 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL373356 | 0.95 | PIK3CB (0.90) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL14702199 | 0.94 | PIK3CB (0.88) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL477634 | 0.94 | PIK3CB (0.88) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL29434918 | 0.94 | PIK3CB (0.88) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL373357 | 0.93 | PIK3CB (0.86) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL14687684 | 0.93 | PIK3CB (0.86) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL477314 | 0.93 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL2947540 | 0.92 | PIK3CB (0.84) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| Hydrochloric Acid SCHEMBL29434925 | 0.92 | PIK3CB (0.98) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| EP-4333822-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | Lead Discovery Center GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| WO-2022233782-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-10 | — | — | WO | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| US-20210353605-A1 | METHODS FOR TREATING ORAL CANCERS | CHANG GUNG UNIVERSITY (TW) | 2021-11-18 | — | — | US | claimed |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-11-17 | — | — | US | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| US-20150254400-A1 | GROUPING FOR CLASSIFYING GASTRIC CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-10 | — | — | US | claimed |
| EP-1864665-B1 | IMMUNOSUPPRESSIVE AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2012-05-16 | — | — | EP | claimed |
| US-7750001-B2 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2010-07-06 | — | — | US | claimed |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-05-15 | — | — | US | claimed |
| EP-1864665-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-12-12 | — | — | EP | claimed |
| US-7071189-B2 | Heterocyclic compound and antitumor agent containing the same as active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-07-04 | — | — | US | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | disclosed |
| US-20040116421-A1 | Heterocyclic compound and antitumor agent containing the same as active ingredient | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1389617-A1 | HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | IL2, NFATC1, CD47 | PIK3CB 2354/4885PIK3CD 1584/4885PIK3CA 2655/4885 |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | PIK3CA, MTOR, PIK3CD | PIK3CB 10/4885PIK3CD 3/4885PIK3CA 1/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | PIK3CB 3531/4885PIK3CD 2996/4885PIK3CA 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.